Phase I evaluation of dianhydrogalactitol (NSC-132313).
A toxicologic evaluation of dianhydrogalactitol in man was completed for a 5- and a 10-day schedule. The maximum tolerated dose was 30 mg/m2/day for the 5-day schedule and 21 mg/m2/day for the 10-day schedule. Dose-limiting myelosuppression occurred with both schedules, with leukopenia and thrombocytopenia being observed at median Days 15 and 19 respectively for the 5-day course and median Days 22 and 26 of the 10-day course. Nausea was infrequent and mild. Responses were obtained in one patient with laryngeal carcinoma and in one patient with adenocarcinoma of the lung.
D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001853:Bone Marrow / Q000187:drug effects; D001854:Bone Marrow Cells; D003864:Depression, Chemical; D004341:Drug Evaluation; D004988:Ethers, Cyclic / Q000627:therapeutic use; D004376:Galactitol / Q000031:analogs & derivatives / Q000627:therapeutic use*; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*; D012075:Remission, Spontaneous; D013402:Sugar Alcohols / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D004988:Ethers, Cyclic; D013402:Sugar Alcohols; D004376:Galactitol